NI
REGN icon

Numeric Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

Numeric Investors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,340
Closed -$599K – 1149
2017
Q3 		$599K Buy
+1,340
New +$638K ﹤0.01% 843
2016
Q4 		– Sell
-1,120
Closed -$450K – 1150
2016
Q3 		$450K Buy
+1,120
New +$449K ﹤0.01% 807

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Numeric Investors's REGN Position: Q4 2017 in Review

Numeric Investors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2017, closing a stake of 1,340 shares — an estimated $599K sold.

Numeric Investors first reported a position in REGN in Q3 2016 and held it in 2 quarters. The position peaked at $599K in Q3 2017. 638 funds tracked by Wall St. Rank hold REGN as of Q4 2017.

  • Numeric Investors reported no remaining Regeneron Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Numeric Investors sold 1,340 Regeneron Pharmaceuticals shares in Q4 2017, an estimated $599K.
  • Numeric Investors first reported a position in Regeneron Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Numeric Investors's Regeneron Pharmaceuticals position peaked at $599K in Q3 2017.
  • 638 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2017.

Based on Numeric Investors's 13F filing for Q4 2017, filed 14 Feb 2018.